Robert M. Gavin Net Worth

The estimated Net Worth of Robert M. Gavin is at least $123 mil dollars as of 1 February 2017. Mr Gavin owns over 1,667 units of Bio-Techne Corp stock worth over $122,508 and over the last 10 years he sold TECH stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Gavin TECH stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Bio-Techne Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 1,667 units of TECH stock worth $122,508 on 1 February 2017.

The largest trade he's ever made was exercising 1,667 units of Bio-Techne Corp stock on 1 February 2017 worth over $122,508. On average, Mr trades about 333 units every 0 days since 2014. As of 1 February 2017 he still owns at least 1,667 units of Bio-Techne Corp stock.

You can see the complete history of Mr Gavin stock trades at the bottom of the page.

Mr. Robert M. Gavin biography

Robert M. Gavin is the VP of Corp. Devel. at Bio-Techne Corp.

How old is Mr Gavin?

Mr Gavin is 53, he's been the VP of Corp. Devel. of Bio-Techne Corp since . There are 15 older and 3 younger executives at Bio-Techne Corp. The oldest executive at Bio-Techne Corp is Roeland Nusse, 70, who is the Independent Director.

What's Mr Gavin's mailing address?

Robert's mailing address filed with the SEC is 614 McKinley Pl NE, Minneapolis, MN 55413, USA.

Insiders trading at Bio-Techne Corp

Over the last 22 years, insiders at Bio-Techne Corp have traded over $37,160,097 worth of Bio-Techne Corp stock and bought 4,361 units worth $454,370 . The most active insiders traders include Charles R. Kummeth, Rupert Vessey, eJohn L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of $964,850. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth $99,919.

What does Bio-Techne Corp do?

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.

Complete history of Mr Gavin stock trades at Bio-Techne Corp

Bio-Techne Corp executives and stock owners

Bio-Techne Corp executives and other stock owners filed with the SEC include:

• Charles Kummeth,
  President, Chief Executive Officer, Director
• Charles R. Kummeth,
  CEO, Pres & Director
• James Hippel,
  Chief Financial Officer, Executive Vice President - Finance
• David Eansor,
  President - Protein Sciences
• Kim Kelderman,
  President - Diagnostics and Genomics
• Brenda Furlow,
  Senior Vice President, General Counsel, Corporate Secretary
• James T. Hippel,
  Exec. VP of Fin. & CFO
• Norman David Eansor,
  Pres of Protein Sciences Segment
• Kim Kelderman,
  Pres of Diagnostics & Genomics
• Brenda S. Furlow J.D.,
  Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer
• Robert Baumgartner,
  Independent Chairman of the Board
• Rupert Vessey,
  Independent Director
• John Higgins,
  Independent Director
• Randolph Steer,
  Independent Director
• Roeland Nusse,
  Independent Director
• Alpna Seth,
  Independent Director
• Joseph Keegan,
  Independent Director
• David Clair,
  IR Contact Officer
• Julie Bushman,
  Independent Director
• Kevin Smyth,
  Sr. VP & Chief Digital Officer
• Luca Cicchetti,
  Managing Director
• Brenda Everson,
  Sr. VP of HR
• Kevin S. Gould,
  Sr. VP of Diagnostics Reagents Division
• Struan Robertson,
  VP of HR
• Robert M. Gavin,
  VP of Corp. Devel.
• Gerry Andros,
  VP of Sales and Marketing
• Karen A Holbrook,
  Director
• Roger C Lucas,
  
• Charles A Dinarello,
  
• J. Fernando Bazan,
  Chief Technical Officer
• Robert M. Gavin,
  Sen. VP Protein Platforms
• Kevin S Gould,
  SVP Clinical Controls
• Kevin J Reagan,
  Senior VP Biotech
• Gregory J Melsen,
  VP Finance and CFO
• Thomas E Oland,
  President
• Howard V Oconnell,
  Director
• Marcel Veronneau,
  Vice Pres-Hematology Oper.
• James A Weatherbee,
  Chief Scientific Officers
• Monica Tsang,
  Vice President of Research
• Christopher S Henney,
  Director
• G A Herbert,
  Director
• Harold J Wiens,
  
• William Geist,
  PRESIDENT, PROTEIN SCIENCES
• Shane Bohnen,
  SVP - General Counsel
• Matthew Mc Manus,
  President - DGS
• Judith V Klimovsky,
  Director